Clinical Research

LEARN ABOUT OUR CLINICAL TRIALS!

Clinical trials are carefully designed research studies that answer specific questions about the safety and effectiveness of preventive techniques, medications, treatments, therapies or surgical techniques. Participation in a clinical trial is strictly voluntary.

Many studies that are developed and available are similar to treatments often referred to as the “gold standard.” Advancements in medicine may lead to improved outcomes through improved results, less discomfort, less time involved in treatment, lower cost, and/or improved safety. At Kidney Associates, we are very selective about studies that we choose to offer to our patients.

Kidney Associates in collaboration with Frenova Renal Research is currently enrolling patients for clinical trials, in order to help our patients live longer, healthier lives.

Am I eligible?

Many studies have strict enrollment criteria. The list of inclusion and exclusion criteria are different for each study. Our dedicated Clinical Research team will assess whether a patient is eligible for a particular study.

If you are interested in learning more about our Clinical Research Program please contact the following personnel:

Lenden Neeper, MS, CCRP
Phone: 303-809-7439
E-mail: lenden.neeper@frenova.com

Patricia Noel, RN, CCRP
Phone: 303-854-7954
E-mail: patricia.noel@frenova.com

Kidney Associates with Frenova are now recruiting for the clinical trials listed below.

TREASURE-CKD Study

This study is a Phase 2b, mechanistic, multicenter, randomized, parallel-placebo controlled, double-blinded, 52 week study that will investigate on the kidney of tirzepatide (10mg or 15mg) injected weekly, compared with placebo, in participants who are overweight or living with obesity and coexisting with chronic kidney disease (CKD) with OR without diabetes. The pharmacological treatment will be combined with a lifestyle intervention consisting of a reduced calorie diet and increased physical activity.

POSIBIL6ESKD Study

This study will be an event-driven, cardiovascular (CV) outcome study designed to evaluate whether the CSL300 dose, administered every 4 weeks versus placebo can reduce the risk of cardiovascular events such as CV death and MI in subjects with ESKD with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.

REGEN-008S1 and REGEN-008S2 Studies

These studies are multi-center, prospective, non-therapeutic, long-term observational extension studies of participants who have been previously enrolled and dosed in previous interventional clinical studies with the REACT product. These subjects will be monitored for up to five years.

KARDIA-3 Study

This is a Phase 2 randomized, double-blind (DB), placebo-controlled, multicenter, 2-cohort study designed to evaluate the efficacy, safety, and pharmacodynamics (PD) of zilebesiran administered subcutaneously (SC) as an add-on therapy in patients with established cardiovascular disease (CVD) or at high cardiovascular (CV) risk with uncontrolled hypertension despite treatment with 2 to 4 standard of care antihypertensive medications.